ibj.com
Lilly’s Omvoh part of company’s expansion into inflammatory bowel disease treatment
A newly approved biologic, Omvoh (mirikizumab), gives another FDA‑approved treatment option for adults with moderate to severe Crohn’s disease and adds to Lilly’s role in IBD care.
The article highlights trial results, company acquisitions, and access/coverage topics that could affect treatment choices and availability.
Adults with Crohn’s or ulcerative colitis; patients on or considering biologics; IBD clinicians; researchers and people tracking drug access and cost.
What To Know
Lilly’s Omvoh (mirikizumab-mrkz) was recently approved by the FDA for moderate to severe Crohn’s disease in adults; the article describes Lilly’s broader expansion into IBD treatment, mentions prior FDA approval for ulcerative colitis, Phase 3 trial remission and endoscopic healing results, and acquisitions and Phase 2 programs aimed at oral therapies targeting α4β7.
Omvoh is a biologic that targets interleukin-23 p19 (IL‑23p19) and the FDA approval cited Phase 3 results showing higher rates of clinical remission and intestinal healing versus placebo at one year. Lilly is pursuing additional IBD approaches, including an oral α4β7-targeting program from Morphic and has submitted or plans submissions outside the U.S.
Coverage by major pharmacy benefit managers and employer cost data are also mentioned. The article is a company- and business-focused report rather than a clinical guideline. It summarizes regulatory and trial outcomes reported by Lilly and public sources; it does not provide treatment recommendations or detailed safety information.
Adults with Crohn’s disease or ulcerative colitis considering biologic options; patients currently on or considering IL‑23 inhibitors; clinicians treating IBD; researchers and industry watchers following IBD drug development and access/cost trends. The story reports FDA approval and trial headline results but is not a primary scientific publication.
Early-stage programs (Phase 2 oral α4β7 approach) are ongoing and do not imply availability. Coverage and cost impact can vary by insurer and employer. For clinical decisions, consult prescribing information and a treating clinician.
The report summarizes regulatory approval, company strategy, and headline Phase 3 outcomes but is not a clinical trial publication. Early‑stage research mentioned (oral α4β7 programs) is still in Phase 2. Coverage and cost details are summarized at a high level; check insurer policies and prescribing information for specifics.
